Companies · Biotechnology

Allele Biotechnology & Pharmaceuticals, Inc.

SAN DIEGO · Biotechnology

Diligence memoA one-page analyst read on Allele Biotechnology & Pharmaceuticals, Inc. — recommendation, valuation, rhythm, risks.
$18.0M
Total raised · real
2
Rounds
1.6×
Latest step-up
Top 35%
Sector rank · raised
Series A
Latest stage · inferred · Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Allele Biotechnology & Pharmaceuticals, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.89× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.7 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Allele Biotechnology & Pharmaceuticals, Inc. is one of 4291 Biotechnology companies tracked from SAN DIEGO. By capital raised it ranks mid-pack (ahead of 66% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2016-10-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2014-08-15 Raised $7.0M (real) Modeled valuation $253M (est)$7.0M$253MSeries A2014Series A · 2016-10-11 Raised $11M (real) Modeled valuation $398M (est)$11M$398MSeries A2016+$11MCumulative $18M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$7.0M · 2014
Series A extension$11.0M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$397.7M
Base estimate est.
$12.0M
Conservative case
$2.2B
Upside case
$50.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $253.1M · 2014-08-152014Series A · modeled $397.7M · 2016-10-112016
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
9.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
26 mo
Avg between rounds
$8.3M/yr
Capital velocity
11.9 yr
On record since
2014
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.5× above median
This company$18.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.0× above median
This company$11.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 6.2× above median
This company$397.7M
Sector median$64.2M

Raised more than 66% of sector peers (real $). Modeled value above 81% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #19 of 157.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Cynvec LLC · Series A Raised $17.4M · modeled $542.3M (est)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Bio-Dent, LTD. LLC · Series A Raised $15.0M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)Allele Biotechnology & Pharmaceuticals, Inc. (this company) Raised $18.0M · modeled $397.7M (est)Allele Biotechnology & Pharmaceuticals, Inc.
CompanyStageRaised · realValue · estvs peer med.
Cynvec LLCSeries A$17.4M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Bio-Dent, LTD. LLCSeries A$15.0M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
Allele Biotechnology & Pharmaceuticals, Inc. this companySeries A$18.0M$397.7M1.89×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$7.0M2014-08-15$31.8M$253.1M85%
Series A$11.0M2016-10-11$50.0M$397.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$7.0M2014-08-15
    • First recorded raise — entered as Series A.
    • 3 investors on this round.
  2. Series A$11.0M2016-10-11
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 4 investors on this round.
Intelligence
2018 ~Q4
Modeled next raise · ~26mo cadence
$17.3M
Modeled next size est.range $11.2M$27.7M
1.6×
Last step-up
$8.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Lin Yang1 other2014-08
Jiwu Wang2014-08
Quishi Fu2014-08
Robert LaPolla2014-08
Shao-Chung Tsai2016-10
Registry & provenance

Allele Biotechnology & Pharmaceuticals, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1617865
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Othera Pharmaceuticals, IncBiotechnologySeries A$18.0M$383.9Msame sector · same stage
Sofregen Medical Inc.BiotechnologySeries A$17.8M$293.0Msame sector · same stage
ArmaGen, Inc.BiotechnologySeries A$18.5M$361.5Msame sector · same stage
Invisible Sentinel, Inc.BiotechnologySeries A$17.5M$275.3Msame sector · same stage
Applied BioCode, Inc.BiotechnologySeries A$17.5M$334.6Msame sector · same stage
Smart Pill CorpBiotechnologySeries A$17.5M$344.0Msame sector · same stage
Cynvec LLCBiotechnologySeries A$17.4M$542.3Msame sector · same stage
GestVision, Inc.BiotechnologySeries A$17.1M$361.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Allogene Therapeutics, Inc.BiotechnologyGrowth/Late$17.5B85%
Allelica, Inc.BiotechnologySeed$51.3M85%
Allevion Therapeutics, Inc.BiotechnologySeed$8.4M84%
Allevi, Inc.BiotechnologySeed$44.6M83%
Diverse Biotech, Inc.PharmaceuticalsSeries A$8.8M83%
PharmaCyte Biotech, Inc.BiotechnologySeries C$40.6M82%
Alliqua BioMedical, Inc.BiotechnologySeries A$100.1M82%
Alloplex Biotherapeutics, Inc.BiotechnologySeries B$271.7M82%
Frequently asked
How much funding has Allele Biotechnology & Pharmaceuticals, Inc. raised?
Allele Biotechnology & Pharmaceuticals, Inc. has raised approximately $18.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Allele Biotechnology & Pharmaceuticals, Inc.'s estimated valuation?
Provath's modeled valuation for Allele Biotechnology & Pharmaceuticals, Inc. is approximately $397.7M (modeled range $12.0M–$2.2B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Allele Biotechnology & Pharmaceuticals, Inc. at?
Allele Biotechnology & Pharmaceuticals, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Oct 11.
What does Allele Biotechnology & Pharmaceuticals, Inc. do and where is it based?
Allele Biotechnology & Pharmaceuticals, Inc. operates in the Biotechnology sector, based in SAN DIEGO.
Explore related

See where Allele Biotechnology & Pharmaceuticals, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Allele Biotechnology & Pharmaceuticals, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.